瑞银-恒瑞医药(600276):HRS-7535减重三期临床达到主要终点,公司预计今年提交中国新药上市申请-HRS-7535 ph3 for weight loss reached primary endpoints;Co. expects to submit China NDA this year-20260707【11页】

发表回复

后才能评论